Entero Therapeutics (NASDAQ:ENTO) Trading 1.5% Higher – Time to Buy?

Shares of Entero Therapeutics, Inc. (NASDAQ:ENTO) rose 1.5% during trading on Thursday . The company traded as high as $3.49 and last traded at $3.33. Approximately 115,128 shares traded hands during trading, a decline of 9% from the average daily volume of 126,532 shares. The stock had previously closed at $3.28.

Analysts Set New Price Targets

Several equities research analysts recently commented on ENTO shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Entero Therapeutics in a report on Tuesday, October 14th. Wall Street Zen raised Entero Therapeutics to a “hold” rating in a research note on Friday, October 3rd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Entero Therapeutics presently has an average rating of “Sell”.

Entero Therapeutics Stock Performance

The company has a 50 day simple moving average of $3.27 and a two-hundred day simple moving average of $3.12. The company has a market cap of $5.29 million, a PE ratio of -1.97 and a beta of 1.19.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Entero Therapeutics stock. Virtu Financial LLC acquired a new stake in Entero Therapeutics, Inc. (NASDAQ:ENTO) during the third quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 11,829 shares of the company’s stock, valued at approximately $59,000. Virtu Financial LLC owned approximately 0.74% of Entero Therapeutics as of its most recent filing with the SEC. Institutional investors own 12.30% of the company’s stock.

Entero Therapeutics Company Profile

Entero Therapeutics, Inc (NASDAQ: ENTO) is a clinical‐stage specialty pharmaceutical company dedicated to developing innovative therapies for patients suffering from rare and debilitating gastrointestinal (GI) disorders. The company leverages targeted delivery technologies designed to localize therapeutic molecules directly to affected regions of the GI tract, aiming to enhance efficacy while minimizing systemic exposure. Entero’s research and development efforts focus on addressing chronic conditions with significant unmet medical needs, including malabsorption syndromes and motility‐related GI diseases.

Entero’s pipeline features multiple lead candidates in varying stages of clinical development.